The estimated Net Worth of Peter Barton Hutt is at least $2.28 Million dollars as of 14 October 2022. Mr. Hutt owns over 3,539 units of Concert Pharmaceuticals Inc stock worth over $276,436 and over the last 20 years he sold CNCE stock worth over $1,877,055. In addition, he makes $125,554 as Independent Director at Concert Pharmaceuticals Inc.
Peter has made over 8 trades of the Concert Pharmaceuticals Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 3,539 units of CNCE stock worth $10,192 on 14 October 2022.
The largest trade he's ever made was exercising 200,000 units of Concert Pharmaceuticals Inc stock on 20 November 2019 worth over $8,000. On average, Peter trades about 7,232 units every 68 days since 2004. As of 14 October 2022 he still owns at least 33,027 units of Concert Pharmaceuticals Inc stock.
You can see the complete history of Mr. Hutt stock trades at the bottom of the page.
Peter Barton Hutt is the Independent Director of Concert Pharmaceuticals Inc. Mr. Hutt has served as a member of our Board since December 2006. Mr. Hutt has practiced law at Covington & Burling LLP, specializing in food and drug law, since 1960 (except for the period from 1971 to 1975) and currently serves as senior counsel. From 1971 to 1975, he was Chief Counsel for the Food and Drug Administration. Mr. Hutt also serves on the board of directors of Immunomedics, Inc. and Q Therapeutics, Inc., as well as numerous private companies. During the last five years, Mr. Hutt previously served on the board of directors of BIND Therapeutics, Inc., DBV Technologies SA, Flex Pharma, Inc., Moderna, Inc., Rubius Therapeutics, Inc., Seres Therapeutics, Inc. and XOMA Corporation. Mr. Hutt received a B.A. from Yale University, an LL.B. from Harvard Law School and an LL.M. from New York University School of Law.
As the Independent Director of Concert Pharmaceuticals Inc, the total compensation of Peter Hutt at Concert Pharmaceuticals Inc is $125,554. There are 10 executives at Concert Pharmaceuticals Inc getting paid more, with Roger Tung having the highest compensation of $2,772,350.
Peter Hutt is 85, he's been the Independent Director of Concert Pharmaceuticals Inc since 2016. There are no older and 15 younger executives at Concert Pharmaceuticals Inc.
Peter's mailing address filed with the SEC is C/O CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON, MA, 02421.
Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V... und Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: